​

Denali Therapeutics (DNLI) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

DNLI Stock Forecast

Denali Therapeutics (DNLI) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $34.80, with a high of $41.00 and a low of $26.00. This represents a 47.65% increase from the last price of $23.57.

$15 $21 $27 $33 $39 $45 High: $41 Avg: $34.8 Low: $26 Last Closed Price: $23.57

DNLI Stock Rating

Denali Therapeutics stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 19 Strong Sell Sell Hold Buy Strong Buy

DNLI Price Target Upside V Benchmarks

TypeNameUpside
StockDenali Therapeutics47.65%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2613
Avg Price Target$31.00$32.00$33.08
Last Closing Price$23.57$23.57$23.57
Upside/Downside31.52%35.77%40.35%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 261171--19
Jun, 261171--19
May, 261171--19
Apr, 261171--19
Mar, 261171--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 23, 2026Morgan Stanley$36.00$23.0656.11%52.74%
Jul 13, 2026Laura ChicoWedbush$26.00$25.332.65%10.31%
Jun 22, 2026Paul MattelsStifel Nicolaus$41.00$23.7672.56%73.95%
May 22, 2026Morgan Stanley$35.00$18.6487.77%48.49%
May 22, 2026Deutsche Bank$31.00$18.6266.49%31.52%
May 08, 2026Laura ChicoWedbush$23.00$20.1114.37%-2.42%
Mar 26, 2026Deutsche Bank$35.00$19.7477.30%48.49%
Mar 02, 2026Andrew TsaiJefferies$40.00$21.0090.48%69.71%
Jan 08, 2026Sean LaamanMorgan Stanley$40.00$16.95135.99%69.71%
Jan 07, 2026Michael YeeUBS$25.00$17.2145.26%6.07%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 23, 2026Morgan StanleyOverweightOverweighthold
Jul 16, 2026Deutsche BankBuyBuyhold
Jul 13, 2026WedbushOutperformOutperformhold
Jun 22, 2026BernsteinHoldHoldhold
Jun 16, 2026UBSBuyBuyhold
May 14, 2026Morgan StanleyOverweightOverweighthold
May 08, 2026WedbushOutperformOutperformhold
Mar 26, 2026Deutsche BankBuyBuyhold
Mar 26, 2026H.C. WainwrightBuyBuyhold
Mar 26, 2026Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.39$-2.60$-1.06$-2.57$-2.97---
Avg Forecast$-2.26$-2.62$-0.99$-2.78$-3.02$-2.49$-1.54$-0.51
High Forecast$-0.70$0.13$-0.90$-2.58$-2.55$-0.55$1.81$0.13
Low Forecast$-3.16$-4.64$-1.17$-2.92$-3.52$-3.48$-3.19$-1.07
Surprise %5.75%-0.76%7.07%-7.55%-1.66%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$48.66M$108.46M$330.53M-----
Avg Forecast$75.99M$109.51M$337.70M$9.31M$42.00M$191.62M$421.67M$657.93M
High Forecast$99.11M$174.56M$359.24M$10.67M$78.12M$194.99M$435.68M$1.22B
Low Forecast$35.56M$20.95M$329.35M$8.54M$1.39M$188.26M$407.65M$21.74M
Surprise %-35.96%-0.96%-2.12%-----

Net Income Forecast

$-550M $-390M $-230M $-70M $90M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-290.58M$-325.99M$-145.22M$-422.77M$-512.54M---
Avg Forecast$-178.35M$-242.60M$-145.22M$-378.17M$-416.75M$-443.44M$-226.87M$-69.54M
High Forecast$-142.68M$-194.08M$-116.18M$-355.10M$-350.51M$-75.73M$249.01M$17.88M
Low Forecast$-214.02M$-291.12M$-174.27M$-401.24M$-482.99M$-477.91M$-437.81M$-147.31M
Surprise %62.93%34.37%-11.79%22.99%---

DNLI Forecast FAQ

Is Denali Therapeutics stock a buy?

Denali Therapeutics stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Denali Therapeutics is a favorable investment for most analysts.

What is Denali Therapeutics's price target?

Denali Therapeutics's price target, set by 19 Wall Street analysts, averages $34.8 over the next 12 months. The price target range spans from $26 at the low end to $41 at the high end, suggesting a potential 47.65% change from the previous closing price of $23.57.

How does Denali Therapeutics stock forecast compare to its benchmarks?

Denali Therapeutics's stock forecast shows a 47.65% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Denali Therapeutics over the past three months?

  • July 2026: 5.26% Strong Buy, 89.47% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 5.26% Strong Buy, 89.47% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 5.26% Strong Buy, 89.47% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.

What is Denali Therapeutics’s EPS forecast?

Denali Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.49, marking a -16.16% decrease from the reported $-2.97 in 2025. Estimates for the following years are $-1.54 in 2027, and $-0.51 in 2028.

What is Denali Therapeutics’s revenue forecast?

Denali Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $191.62M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $421.67M, and $657.93M for 2028.

What is Denali Therapeutics’s net income forecast?

Denali Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-443M, representing a -13.48% decrease from the reported $-513M in 2025. Projections indicate $-227M in 2027, and $-69.544M in 2028.